Barr confirms patent challenge of Amrix extended-release capsules
Barr has filed its abbreviated new drug application (ANDA) containing a paragraph IV certification for a generic version of Amrix with the FDA, and following receipt of the
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.